Document is current
Any future updates will be listed below
-
Authors
Fraterman, Itske https://orcid.org/0000-0001-7974-8422
Reijers, Irene L. M.
Dimitriadis, Petros https://orcid.org/0000-0002-3546-285X
Broeks, Annegien
Gonzalez, M.
Menzies, A. M. M.
Lopez-Yurda, Marta https://orcid.org/0000-0003-3678-3222
Kapiteijn, Ellen
van der Veldt, Astrid A. M.
Suijkerbuijk, Karijn P. M.
Hospers, Geke A. P. https://orcid.org/0000-0002-3047-7892
Long, Georgina V. https://orcid.org/0000-0001-8894-3545
Blank, Christian U. https://orcid.org/0000-0002-7945-5846
van de Poll-Franse, Lonneke V. https://orcid.org/0000-0003-0413-6872
- License Information
-
More Information
Article History
Received: 2 May 2023
Accepted: 5 October 2023
First Online: 13 November 2023
Competing interests
: No author has received financial support for the work on this paper, and no medical writer was involved at any stage of the preparation of this paper. I.L.M.R. and P.D. report financial interest in Signature Oncology and will receive some possible revenues if the IFNγ signature is being developed as a clinical companion diagnostic. A.M.M.M. has served on advisory boards for Bristol Myers Squibb (BMS), Merck Sharp & Dohme (MSD), Novartis, Roche, Pierre Fabre and QBiotics. E.K. received honoraria for consultancy/advisory relationships (all paid to the institute) from BMS, Novartis, Merck, Lilly and Pierre Fabre, and received research grants not related to this paper from BMS, Pierre Fabre and Delcath. A.A.M.v.d.V. received compensation for advisory roles and honoraria (all paid to the institute) from BMS, MSD, Merck, Roche, Eisai, Pfizer, Sanofi, Novartis, Pierre Fabre and Ipsen. K.P.M.S. received compensation for advisory roles and honoraria (all paid to the institute) from BMS, MSD, Novartis, Pierre Fabre and Abbvie, and received research funding from Novartis, TigaTx and BMS. G.A.P.H. received compensation for consulting and advisory roles (all paid to the institute) from Amgen, Roche, MSD, BMS, Pfizer, Novartis and Pierre Fabre, and received research grants (paid to the institute) from BMS and Seerave. G.V.L. is consultant advisor for Agenus, Amgen, Array Biopharma, AstraZeneca, Boehringer Ingelheim, BMS, Evaxion, Hexal AG (Sandoz Company), Highlight Therapeutics, Innovent Biologics, MSD, Novartis, Oncosec, PHMR Ltd, Pierre Fabre, Provectus, QBiotics and Regeneron. C.U.B. reports receiving compensation for advisory roles from BMS, MSD, Roche, Novartis, GlaxoSmithKline, AstraZeneca, Pfizer, Eli Lilly, Genmab, Pierre Fabre and Third Rock Ventures, and receiving research funding from BMS, MSD, Novartis, 4SC and NanoString. Furthermore, C.U.B. reports to be co-founder of Immagene BV. All compensations and funding for C.U.B. were paid to the institute, except for Third Rock Ventures and Immagene. The remaining authors declare no competing interests.
